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Abstract 
 
ESAC, the EURL ECVAM Scientific Advisory Committee, advises EURL ECVAM on scientific 
issues. Its main role is to conduct independent peer review of validation studies of 
alternative test methods and to assess their scientific validity for a given purpose. The 
committee reviews the appropriateness of study design and management, the quality of 
results obtained and the plausibility of the conclusions drawn. ESAC peer reviews are 
formally initiated with a EURL ECVAM Request for ESAC Advice, which provides the 
necessary background for the peer-review and establishes its objectives, timelines and the 
questions to be addressed. The peer review is normally prepared by specialised ESAC 
Working Groups. ESAC's advice to EURL ECVAM is formally provided as 'ESAC Opinions' and 
'Working Group Reports' at the end of the peer review. ESAC may also issue Opinions on 
other scientific issues of relevance to the work and mission of EURL ECVAM but not directly 
related to a specific alternative test method.   
The ESAC Opinion expressed in this report relates to the peer-review of the AR-CALUX® in 
vitro test method. 
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Ispra, 5 June 2019 
ESAC Opinion 
 
In 2014, the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) 
launched a validation study of the AR-CALUX® in vitro test method with the overall goal, 
provided the validation study would be successful, of proposing the test method to the 
Organisation for Economic Co-operation and Development (OECD) to become a Test 
Guideline (TG). In March 2019, the EURL ECVAM Scientific Advisory Committee (ESAC) 
(Annex 1) was formally asked by EURL ECVAM to conduct an independent peer review of 
the AR-CALUX® and the EURL ECVAM coordinated validation study and to provide a 
scientific opinion on the method’s scientific validity. An ESAC Working Group (WG) was 
established for this purpose (Annex 1). The WG met in May 2019 to deliberate on: (1) the 
scientific basis and biological relevance of the method, (2) its overall performance as 
assessed during the validation study and (3) its applicability and limitations. Based on its 
independent assessment, the ESAC WG delivered a detailed peer review report (Annex 2) to 
support the development of this opinion. The analysis and conclusions of the ESAC WG were 
based primarily on the EURL ECVAM Validation Study Report, including all the relevant study 
Annexes and supporting documents. The assessment also included direct requests from the 
ESAC WG to the test developer for supporting information. 
At its 45th meeting, held on 3-5 June 2019 at EURL ECVAM, Ispra, Italy, the non-
Commission members of ESAC unanimously endorsed this opinion. Based on the available 
information, the existing scientific literature and the experts' own extensive experience as 
detailed in the ESAC WG report, the ESAC unanimously concluded the following: 
The AR-CALUX® is a scientifically sound and biologically relevant method for the 
evaluation of androgen receptor agonism and antagonism 
The AR-CALUX® is designed to capture one type of endocrine activity, specifically, binding 
to the androgen receptor, coupled to the receptor dimerisation and followed by DNA 
activation, thus covering the molecular initiating event for androgen-mediated adverse 
outcomes. This assay evaluates both agonism and antagonism. The readout of the assay is 
by luciferase activation, via DNA transcription. The principles of reporter gene 
(transactivation) assays and the luciferase response are well established (documented) and 
accepted by the scientific and regulatory communities. Similar assays have been adopted 
into OECD Test Guidelines (e.g., Test Guidelines No. 442D, 455, 457 and 458) and the latter 
three Test Guidelines are included in guidance on assessment of endocrine disruption 
(OECD Guidance Document No. 150). 
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The performance characteristics of the AR-CALUX® are fit for the regulatory 
purpose(s) for which they are defined 
Within- and between-laboratory reproducibility was evaluated with twenty chemicals, all 
tested in four laboratories. The reproducibility of the assay for androgen receptor agonism 
and antagonism was ≥94% within laboratories and 100% between laboratories.  
Twenty-three chemicals could be used to evaluate concordance of the AR-CALUX® 
predictions with the reference classifications published by the Interagency Coordinating 
Committee on the Validation of Alternative Methods (ICCVAM). Based on the positive or 
negative classification, as defined in the study protocols, the concordance was excellent. 
For agonism, positive concordance was >90%, negative concordance was 100% and overall 
concordance was >93%. For antagonism, all parameters were 100%. These performance 
characteristics demonstrate a robust test method for categorisation of agonism and 
antagonism of the androgen receptor for regulatory purposes. In line with the Standard 
Operating Procedure, a number of concentration-based parameters, e.g., EC50, PC10, were 
calculated, and the former were used to evaluate coefficient of variation for the assay, 
demonstrating good reproducibility (see additional note below). 
The AR-CALUX® is generally applicable to the determination of androgen receptor 
agonism and antagonism of test chemicals 
The AR-CALUX® is ready for screening purposes, mechanistic studies and hazard 
assessment, as well as for generating supporting information for regulatory prioritisation 
and decision-making. The ESAC also considers that the assay is suitable for high-
throughput screening (HTS) use.  
The validation set of forty-six compounds is larger than usually employed and expands 
on available data from validation of other ARTAs. The chemicals selection was supported by 
the OECD Validation Management Group Non-Animal (VMG-NA) and the International 
Cooperation on Alternative Test Methods (ICATM). 
The addition of the application of specificity testing using a comparative R2 rule is 
considered by the ESAC as a useful additional pragmatic statistical tool to distinguish 
between true and false antagonists in the manner used in this validation study. 
Expansion to other areas of use (e.g., testing of nanomaterials, medical devices) may 
entail suitable extension of the validation procedures, with respect to the predefined 
performance criteria. 
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Conclusion and Recommendation 
The ESAC concludes that the AR-CALUX® is a robust test method for 
categorisation of agonism and antagonism of the androgen receptor. The test 
method is ready for screening purposes, mechanistic studies and hazard 
assessment, as well as for generating supporting information for regulatory 
prioritisation and decision-making. 
 
Additional note on using concentration-response in in vitro assays: 
The determination of the predictive capacity of in vitro assays is often done by 
dichotomous categorisation of positives and negatives. The assay data, however, often 
contain a wealth of concentration-response information, which allows (relative) potency 
assessment of test compounds. Potency information is essential input for the use of assay 
data in approaches towards quantitative hazard and risk assessment, such as Integrated 
Approaches to Testing and Assessment (IATA), Defined Approaches (DAs), quantitative 
Adverse Outcome Pathways (AOPs), Quantitative Structure-Activity Relationships (QSARs), 
and in silico modelling. As in vitro methods continue to be developed and validated, it is 
advisable that possibilities are sought for maximising the use of the concentration-
response data in the assessment of relevance of in vitro assays. 
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ESAC Working Group 
 
Full title: ESAC Working Group on the AR-CALUX® Test Method  
 
Abbreviated title:  ESAC WG AR-CALUX® 
 
The ESAC WG was established in March 2019 by written procedure to assist in the production of an 
ESAC Opinion on the scientific validity of the AR-CALUX® in vitro test method to assess the 
androgenic and antiandrogenic activity of chemicals. 
This report was prepared at the request of EURL ECVAM by the "ESAC Working Group AR-CALUX®" 
(ESAC WG), which was charged with conducting a detailed scientific peer review of the EURL ECVAM 
coordinated validation study of the AR-CALUX® in vitro test method. The basis for the scientific peer 
review was the EURL ECVAM Request for ESAC Advice approved by the ESAC by written procedure 
following the ESAC44 plenary meeting of December 2018 (ESAC request 2019-02). 
The ESAC WG met at EURL ECVAM on 02-03/05/2019 to conduct its peer review. This ESAC WG 
Report was endorsed by the ESAC WG on 29/05/2019 and represents its consensus view. The Report 
was endorsed by the ESAC on 05/06/2019. 
 
The ESAC WG had the following members: 
• Prof. Ian COTGREAVE (ESAC Core Member, WG Chair) 
• Dr. Rebecca CLEWELL (ESAC Core Member, WG Rapporteur) 
• Prof. Annette KOPP-SCHNEIDER (ESAC Core Member) 
• Dr. José Maria NAVAS ANTÓN (ESAC Core Member) 
• Prof. Aldert PIERSMA (ESAC Core Member) 
• Dr. Miriam JACOBS (ESAC Ad-hoc Member) 
Observer 
• Dr. Hajime KOJIMA (JaCVAM) 
 
 
EURL ECVAM (Secretariat):  
• Dr. João BARROSO (ESAC Coordinator) 
• Dr. Anne MILCAMPS 
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ABBREVIATIONS USED IN THE DOCUMENT 
• AR   Androgen Receptor 
• ARTA   Androgen Receptor Transactivation  Assay 
• BLR   Between-laboratory reproducibility 
• ESAC   EURL ECVAM Scientific Advisory Committee 
• ESAC WG  ESAC Working Group 
• EU-NETVAL  European Union Network of Laboratories for the Validation of 
   Alternative Methods 
• EURL ECVAM   European Union Reference Laboratory for Alternatives to 
   Animal Testing 
• GLP   Good Laboratory Practice 
• ICATM   International Cooperation on Alternative Test Methods 
• ICCVAM  Interagency Coordinating Committee on the Validation of Alternative
   Methods 
• JRC   Joint Research Centre 
• OECD   Organisation for Economic Co-operation and Development  
• QA   Quality Assurance 
• QC   Quality Control 
• SOP   Standard Operating Procedure 
• TG   Test Guideline 
• TGP   Test Guidelines Programme 
• VMG   Validation Management Group 
• VMG-NA  Validation Management Group Non-Animal 
• VSR   Validation Study Report 
• WLR   Within-laboratory reproducibility 
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1. Study objective and design 
1.1 Analysis of the clarity of the study objective's definition 
(a) ESAC WG summary of the study objective as outlined in the Validation Study Report 
In 2014, EURL ECVAM launched a validation study of the AR-CALUX® method with the overall goal, 
provided the validation study would be successful, of proposing the test method to OECD to become 
a Test Guideline (TG). In March 2019, the ESAC was formally asked to provide independent review 
and provide scientific opinion to EURL ECVAM on the AR-CALUX® method. The ESAC AR-CALUX® 
Working Group (WG) was formed and met in May 2019 to deliberate on: (1) the scientific basis and 
biological relevance of the method, (2) its overall performance as assessed during the validation 
study and (3) its applicability and limitations. 
 
(b) Appraisal of clarity of study objective as outlined in the Validation Study Report 
The ESAC agrees that the study objectives are clear in the Validation Study Report (VSR). 
 
1.2 Quality of the background provided concerning the purpose of the test 
method  
The VSR clearly describes the intended application of the AR-CALUX® test method. The regulatory 
testing purpose of the test method is to screen for human relevant androgen receptor (AR) agonism 
and antagonism, as part of level 2 of the OECD conceptual framework for the testing and 
assessment of endocrine disruptors. It is an additional method to the current OECD TG 458, which is 
also an Androgen Receptor Transactivation  Assay (ARTA)  (OECD 2016), and the regulatory 
applications and guidance can be found in OECD GD 150 (OECD 2018). 
 
(a) Analysis of the scientific rationale provided in the Validation Study Report 
The assay is designed to capture the downstream events following binding to the AR, subsequent 
receptor dimerisation, followed by DNA activation, thus covering the molecular initiating event for 
androgen-mediated adverse outcomes. The readout of the assay is luciferase signal activated via 
DNA transcription and transactivation of a luciferase reporter construct.  
 
(b) Analysis of the regulatory rationale provided in the Validation Study Report 
Internationally, there is a well-recognised regulatory need to provide test systems for the detection 
of chemicals with endocrine activity, focusing at first on estrogen, androgen, thyroid and 
steroidogenesis modalities. Whilst in vitro assays for estrogenic and steroidogenic modalities have 
been developed as TGs, the development and validation of androgen receptor and thyroid in vitro 
test methods are taking longer.   
The international regulatory need for AR assays was reflected several years ago, by the acceptance 
of the European Commission (EC) proposal (standard project submission form) to the OECD Working 
Group of National Coordinators of the Test Guidelines Programme (WNT), to conduct the AR-CALUX® 
validation as part of the OECD Test Guidelines Programme (TGP). This is clearly reflected in the VSR.   
At the time of the project proposal submission, there were no successfully validated ARTA(s), though 
the AR Ecoscreen, led by Japan, was going through validation. Other AR binding assays were 
dropped from the TGP, as the lead countries were no longer in a position to continue validation 
work, and also because there was an international regulatory preference for test methods that 
included more downstream information. e.g., DNA transactivation. The AR Ecoscreen and AR-CALUX® 
test methods, both being ARTAs, therefore met a critical gap as identified in the OECD endocrine 
disruptor testing and assessment work programme. The AR Ecoscreen was successfully validated 
and peer reviewed in 2015, leading to TG approval and declassification in 2016 (TG 458). The AR-
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CALUX® assay validation was already well underway, and provides an additional AR modality assay, 
also using the luciferase signaling technology. It is therefore suitable to join the current TG 458 with 
the same regulatory rationale. 
 
1.3 Appraisal of the appropriateness of the study design 
The study and data reported in the VSR comply with the principles and criteria set out in the OECD 
Guidance Document on the Validation and International Acceptance of New or Updated Test 
Methods for Hazard Assessment (No. 34, OECD, 2005), and described in the generally accepted 
Modular Approach to validation (Hartung et al., 2004). 
Number of laboratories: The number of laboratories was originally three, which is satisfactory. A 
fourth laboratory was added, as a precautionary measure, when there were concerns regarding the 
performance of one of the three laboratories early on in the transfer and reproducibility phases of 
the study. However, this laboratory was able to take appropriate corrective action by deadlines 
given and completed the reproducibility study. Therefore, the results from the fourth laboratory are 
included in the final analysis. The fourth laboratory is not essential to the validation, but does 
augment the data. 
Organisation of the study: This study was organised according to standard Joint Research Centre 
(JRC) procedures using EU-NETVAL laboratories, and the ESAC supports this process. 
Chemical selection: The procedure for chemical selection, which was carried out by EURL ECVAM 
in consultation with the OECD Validation Management Group Non-Animal (VMG-NA) and the 
International Cooperation on Alternative Test Methods (ICATM) was deemed appropriate by the 
ESAC. However, with regard to the use of mixtures, e.g., Arachlor 1254, ESAC warns against using 
ill-defined mixtures in validation studies. In addition, the ESAC recommends that the use of 
chemicals on the Stockholm Persistent Organic Pollutants (POPs) Convention lists or banned in 
certain OECD member countries (e.g., Arachlor 1254, PCBs, DDT, methoxychlor) should preferably be 
avoided in the proficiency chemical set.  
Quality Assurance (QA) of data: Good Laboratory Practice (GLP) processes were followed in 
three laboratories. The fourth laboratory, which is also the test method developer, explained that 
although they do not conduct this assay to full GLP documented inspection standards in-house, they 
do have an independent Quality Control (QC) officer, and do follow GLP-like processes (see section 
3.1). 
Statistician independence: To ensure objectivity, the statistical analysis was conducted in a 
blinded manner by EURL ECVAM, with no possibility for any subjective judgement. 
 
1.4 Appropriateness of the statistical evaluation 
Standard EURL ECVAM approaches were used, with the addition of the application of specificity 
testing using a comparative R2 rule to distinguish between true and false antagonists. This addition 
is considered by the ESAC as a useful pragmatic statistical tool for this validation study. However, it 
is sufficient to base the R2 rule solely on correlation. Linear regression is not appropriate in this 
situation, because both variables are associated with error. This recommendation will neither affect 
the results of the validation nor the conclusions drawn.  
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2. Collection of existing data 
2.1 Existing data used as reference data 
The following sources were used for reference data in the VSR: 
• Chemical selection for the validation study: Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM) recommendation list of 2003; AR Ecoscreen 
results from 2005 (Araki et al., 2005), and from the validation study and TG 458 (OECD, 
2016); AR-CALUX® published results (van der Burg et al., 2010) and PALM assay results 
(Freyberger et al., 2012).   
• Assessment of predictive capacity (categorisation): ICCVAM list of 2017 (Kleinstreuer et al., 
2017); ARTA of Japan (TG 458); ARTA of Korea (validation study report); Tox21 lux, Tox21 
bla; AR-pathway model. 
• Comparison of variability: 
• ER-CALUX® (TG 455):  
• For agonist testing (log EC50) (n=17): 1.2% to 3.1% CV 
• For antagonist testing (log IC50) (n=4): 0.5% to 1.6% CV 
• ARTA of Japan (EcoScreen (TG 458 OECD 2016))  
• For agonist testing (log PC50) (n=3):  0.38% to 1.53% CV 
• For antagonist testing (log IC50) (n=3): 0.84% to 1.15% CV 
The ESAC considers these data appropriate for their use in this validation study. 
 
2.2 Existing data used as testing data 
Not Applicable. 
 
2.3 Search strategy for retrieving existing data 
The ESAC supports the search strategy, which was already agreed by the VMG-NA, ICATM and 
Tox21 partners (see Annex 13.3 of the VSR). 
 
2.4 Selection criteria applied to existing data 
The ESAC agrees with the pre-defined criteria applied in data selection (see Annex 13.3 of the VSR). 
The ESAC also appreciated the transparency of the description of the selection criteria. 
 
 
3. Quality aspects relating to data generated during the 
study 
3.1 Quality assurance systems used when generating the data 
Good In Vitro Method Practice (GIVIMP) is not applicable, as it was published in 2018, which was 
after the completion of validation data collection. Nevertheless, many of the principles of practice 
were applied in the validation study. Good Cell Culture Practice (GCCP) is generally used in SOP 
development, but does not need to be specified. Full GLP compliance is not a requirement for test 
method development or validation. Nonetheless, the use of GLP was ensured in three test facilities 
and confirmed by appropriate Statements. The fourth laboratory is ISO accredited for two other 
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methods, and has an in-house QC officer, as well as following GLP-like practices. The ESAC 
endorses the quality assurance measures taken in this validation study. 
 
3.2 Quality check of the generated data prior to analysis 
See Section 3.1.  Furthermore, in addition to in-house quality assurance procedures, QA checks were 
performed at EURL ECVAM. 
 
 
4. Quality of data used for the purpose of the study (existing 
and newly generated) 
4.1 Overall quality of the evaluated testing data (newly generated or existing) 
In the initial transfer phase, several technical problems were incurred, which led to rejection of data 
based on the predefined acceptance criteria. This was overcome in later phases, with assistance 
from EURL ECVAM and the test method developer. This resulted in average CVs under 5% in the 
final predictive test phase, which is considered by the ESAC as excellent.  
4.2 Quality of the reference data for evaluating relevance1 
The biological relevance of the test system is established, and the reference data used for 
comparison includes established mechanisms for both agonism and antagonism. Comparisons were 
made with validation reference data from similar androgen receptor stably transfected 
transactivation assay (STTA) – AR EcoScreen (Japan) and ARTA (Korea), as well as with 
supplementary sources, including Tox21 AR transactivation assays, and the EPA AR pathway model. 
The performance values were calculated in comparison to the more recent ICCVAM reference lists. 
The ESAC considers these comparisons are appropriate.  
Comparison with in vivo Hershberger data was performed by EURL ECVAM, but is not considered by 
ESAC to be essential to the final conclusions, because the Hershberger is not considered to be 
reliable. ESAC suggested  comparison of the AR-CALUX® with data with the validated 21 Day 
Androgenised Female Stickleback Endocrine Screening Assay (OECD, 2011), as well as the Rapid 
Androgen Disruption Adverse outcome Reporter (RADAR) assay (Sébillot et al., 2014), which is 
currently in validation. These comparisons were conducted by EURL ECVAM, but the currently 
available Stickleback and RADAR data are considered too limited to yield a useful comparison at 
this time. 
 
4.3 Sufficiency of the evaluated data in view of the study objective 
The ESAC considers the quality of the entire data set sufficient to draw robust conclusions (see 4.1 
and 4.2). 
 
 
 
                                                          
1 OECD guidance document Nr. 34 on validation defines relevance as follows: "Description of relationship of 
the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the 
extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates 
consideration of accuracy (concordance) of a test method." 
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5. Test definition (Module 1) 
5.1 Quality and completeness of the overall test definition 
With regard to the overall test system, relevance, criteria and protocol, the ESAC considers that: 
a) The test system is well described, but there is a lack of information on cell line characterisation.  
Low phase I, II and III activities have been characterised in the cell line (personal communication 
with test developers), and using TempoSEQ this is regularly checked and guaranteed on clones 
provided to end users. The ESAC understands that this information will be included in an updated 
VSR. 
b) The method has high relevance to the activation of the androgen receptor. 
c) The criteria were strict and delivered desirable CV characteristics. 
d) The SOPs are sufficiently described and several existing VMG recommendations in the revised 
SOPs are endorsed by the ESAC. ESAC also recommends the use of bold text and cautionary notes 
for critical elements. These include: 
 The preferred use of commercial premixed (10%) stocks of Triton X-100. 
 The need to use high purity DMSO. New lots should be tested against the inclusion 
criteria. 
 The need to ensure appropriate temperature of luciferin in the assay. 
 The importance of a priori checking of glassware and plasticware for performance, 
considering also effects of chemical contamination during dilution. 
 The need for a priori testing of new lots of serum for performance as well as 
mycoplasma contamination. 
 
5.2 Quality and completeness of the documentation concerning SOPs and prediction 
models 
The ESAC supports the use of the SOPs, with the planned revisions by EURL ECVAM. 
 
 
6. Test materials 
6.1 Sufficiency of the number of evaluated test items in view of the study 
objective 
In the view of the ESAC the numbers of test items exceed the minimum acceptable number. Further, 
the expanded number of chemicals tested in this validation study compared to other ARTA assays is 
appreciated. 
 
6.2 Representativeness of the test items with respect to applicability 
The ESAC considers that the chemical selection process to derive structural diversity was well 
thought-out and executed with appropriate consultation. Appropriate diversity was evident for the 
antagonist and negative test sets. It is acknowledged that fewer known agonists are available, and 
therefore the test set is clustered around the steroid structures. As with any in vitro assay, 
chemicals being difficult to test (Volatile Organic Compounds (VOCs) and certain lipophilics, etc.) are 
not included in the validation study. 
 
 
 
 
ANNEX 2 - ESAC WORKING GROUP REPORT  Page | 19 
7. Within-laboratory reproducibility (WLR) (Module 2) 
7.1 Assessment of repeatability and reproducibility in the same laboratory 
The ESAC agrees that this is fit for purpose and considers that good concordance in predictions 
amongst runs was achieved. Repeatability versus reproducibility was not systematically considered 
in the study design. However, based on the low CVs, ESAC is confident in the reproducibility. 
The lead laboratory, BDS did provide historic control data in response to ESAC questions on historic 
WLR. These data are satisfactory and in line with ESAC’s overall conclusions. 
 
7.2 Conclusion on within-laboratory reproducibility as assessed by the study 
The conclusions on within-laboratory repeatability and reproducibility are justified by the data as 
evaluated. 
 
 
8. Transferability (Module 3) 
8.1 Quality of design and analysis of the transfer phase 
The ESAC considers that the design of the transfer phase and the pre-described criteria for the 
phase were appropriate and effective. 
 
8.2 Conclusion on transferability to a naïve laboratory / naïve laboratories as 
assessed by the study 
Potential critical issues have been identified in the protocols and the SOPs appropriately amended. 
This supports effective transfer to a naïve laboratory. 
 
 
9. Between-laboratory reproducibility (BLR) (Module 4) 
9.1 Assessment of reproducibility in different laboratories 
The BLR was assessed both as %CV (intrinsic data variability) and as concordance of predictions 
between laboratories. The BLR was considered by the ESAC to be good. 
 
9.2 Conclusion on between-laboratory reproducibility as assessed by the study 
The ESAC considers this to be good. 
 
 
10. Predictive capacity and overall relevance (Module 5)  
10.1 Adequacy of the assessment of the predictive capacity in view of the 
purpose 
The ESAC considers the assay as fit for the intended purpose as described in the validation report 
(see section 4.2).  
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10.2 Overall relevance (biological relevance and accuracy) of the test method in 
view of the purpose 
The ESAC considers that the assay clearly addresses the androgen receptor mode of action at the 
cellular level. The assay is relevant for the prediction of a primary component in androgen receptor 
mediated response and, as such, is relevant for regulatory use. However, it is acknowledged that 
steroid hormones can be active to differing degrees amongst the steroid receptors, as witnessed by 
the low activity of progesterone and oestrogen in the test system. This entails that steroids other 
than androgens will show activity in this assay and is consistent with in vivo endocrine biology. 
 
 
11. Applicability domain (Module 6)  
11.1 Appropriateness of study design to conclude on applicability domain, 
limitations and exclusions 
The ESAC considers that the chemical space coverage is more than adequate for the validation and 
expands on available data from validation of other ARTAs. Indeed, the chemical selection was 
clearly supported by the OECD VMG-NA throughout. In addition, mapping of the chemical space 
(based on chemical structural features) demonstrates that the validation chemical selection 
provided appropriate coverage of the REACH chemical space, as much as can be achieved with the 
limited number of chemicals that can feasibly be tested in a validation study. 
 
11.2 Quality of the description of applicability domain, limitations, exclusions 
The ESAC considers that the applicability domain is sufficiently described with respect to the aims 
of the validation study. 
Expansion to other areas of use, such as testing of nano-materials and medical device materials, 
may entail suitable extension of the validation procedures, with respect to the predefined 
performance criteria. 
As identified in other validation studies using the luciferin/luciferase reporter system, the use of 
some phytochemicals, such as genistein and daidzein, can non-specifically augment the signals 
reported in the luminometer, leading to false positives. 
 
 
12. Performance standards (Module 7)  
12.1 Adequacy of the proposed Essential Test Method Components 
Not Applicable. 
 
12.2 Adequacy of the proposed Reference Chemicals 
Not Applicable. 
 
12.3 Adequacy of the proposed performance target values 
Not Applicable. 
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13. Readiness for standardised use 
13.1 Assessment of the readiness for regulatory purposes 
The ESAC considers that the assay is ready for regulatory purposes, as all requirements have been 
met during validation. 
 
13.2 Assessment of the readiness for other uses 
The AR-CALUX® is also ready for screening purposes, mechanistic studies and for supporting 
information for hazard/risk assessment. 
 
13.3 Critical aspects impacting on standardised use 
The ESAC considers that the assay is suitable for high-throughput screening (HTS) use (van der Burg 
et al., 2015). The ESAC have seen letters between ATCC and BDS from 2002 and are satisfied with 
respect to intellectual property (IP) considerations and permissions for use. Fair, Reasonable, and 
Non-Discriminatory (FRAND) conditions will need to be applied (OECD, 2019). 
 
13.4 Gap analysis 
The current description of the model lacks a full characterisation of the presence of the relevant 
hormone-dependent receptors and down-stream regulators in the test system that may affect the 
read-out. However, the ESAC acknowledges the authentication of the cell line, as performed by the 
JRC. In addition, the ESAC considers the low expression of the glucocorticoid receptor/mechanism in 
the AR-CALUX® cells to be important in minimising potential receptor cross-talk in the system. 
 
 
14. Other considerations 
A clearer (GANTT) indication of the time-lines associated with each phase of the validation could be 
provided. 
The first classifier utilises “positive”, “negative” and “inconclusive” categories. ESAC agrees with the 
change proposed by the VMG, to use a classifier using only two categories, “positive” and “negative”. 
ESAC also agrees to the use of the interpolation approach, to predict the value at a dilution factor 
of 2, to re-evaluate the validation data and provide proof of concept for the final SOP (with a 
dilution factor of 2). This is an appropriate adaptation in response to the validation data. 
 
 
15. Conclusions on the study 
15.1 ESAC WG summary of the results and conclusions of the study 
With the recommendations provided, this assay is considered ready to be taken forward to Test 
Guideline development. 
 
15.2 Extent to which study conclusions are justified by the study results alone 
Based on the appraisal performed by the ESAC, the study conclusions are clearly justified by the 
study results alone. 
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15.3 Extent to which conclusions are plausible in the context of existing 
information 
Considering the lack of chemicals with established androgenic properties, the chemical coverage 
utilised in the validation was commendable. 
 
 
16. Recommendations 
16.1 General recommendations 
It is appreciated  that, subsequent to the validation study, the AR-CALUX® assay has been expanded 
to include aspects of metabolic capacity (van Vugt-Lussenburg et al., 2018), in concordance with 
the recommendations of the  OECD detailed review paper (DRP) 97 (OECD, 2008). This could 
potentially be used to extend biological relevance of the test for chemicals that are activated or 
inactivated via metabolism. 
The determination of the predictive capacity of in vitro assays is often done by dichotomous 
categorisation of positives and negatives. The assay data, however, often contain a wealth of 
concentration-response information, which allows (relative) potency assessment of test compounds.  
Potency information is essential input for the use of assay data in approaches towards quantitative 
hazard and risk assessment, such as Integrated Approaches to Testing and Assessment (IATA), 
Defined Approaches (DAs), quantitative Adverse Outcome Pathways (AOPs), Quantitative Structure-
Activity Relationships (QSARs), and in silico modelling.  As in vitro methods continue to be developed 
and validated, it is advisable that possibilities are sought for maximising the use of the 
concentration-response data in the assessment of relevance of in vitro assays. 
 
16.2 Specific recommendations (e.g. concerning improvement of SOPs) 
In addition to the specific recommendations provided by the VMG, and provided in section 5.1 
above, eventual use of drying ovens in glass-ware re-use should account for any potential 
contaminations from the plastic/rubber linings and other fixtures in the oven. This extends to 
consideration of potential contamination from all lab-ware, and from the local laboratory 
environment (building material, air, water, etc.). The test users should also avoid the use of 
glassware with any protective coatings. Finally, including potency in data interpretation (such as 
with IC50 or PC10 data calculated in this validation study) would improve and facilitate broader 
(regulatory) use of the data generated by the assay (see section 16.1). 
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